Report
Aelis Farma - FY23 results: cash runway reiterated + 2 clinical readouts within sight
*Last night, Aelis shared its FY23 results, most notably reiterating cash runway until 2025-end, and providing a 2024 outlook.*This year, we primarily look forward to the Ph2b and Ph1/2 readouts for cannabis use disorder (CUD) and Down syndrome (DS), respectively, after the summer. While mid-2024 was previously already indicated for CUD, recruitment hurdles (which have been solved by now) have pushed readout timing for the DS study with a few months (previous guidance end of Q1 '24). On a positive note, this forced Aelis to engage more intensely with the DS community which should benefit the follow-up Ph2 study.*We trim
Underlying
AELIS FARMA SA
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.